CAM
TVRD

ClariVest Asset Management’s Tvardi Therapeutics TVRD Stock Holding History

ClariVest Asset Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1
Closed – – 674
2015
Q4 		$0 Hold
1
– – ﹤0.01% 664
2015
Q3 		$0 Hold
1
– – ﹤0.01% 661
2015
Q2 		$0 Hold
1
– – ﹤0.01% 662
2015
Q1 		$0 Hold
1
– – ﹤0.01% 649
2014
Q4 		$0 Sell
1
-891
-100% -$287K ﹤0.01% 621
2014
Q3 		$270K Hold
892
– – 0.01% 334
2014
Q2 		$546K Buy
+892
New +$480K 0.02% 274

Other funds holding TVRD

RCP
Rho Capital Partners New York $20.4M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
CPM
Chesapeake Partners Management Baltimore, Maryland $669M AUM 1.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ClariVest Asset Management's TVRD Position: Q1 2016 in Review

ClariVest Asset Management sold out of Tvardi Therapeutics (TVRD) in Q1 2016, closing a stake of 1 share.

ClariVest Asset Management first reported a position in TVRD in Q2 2014 and held it in 7 quarters. The position peaked at $546K in Q2 2014. 93 funds tracked by Wall St. Rank hold TVRD as of Q1 2016.

  • ClariVest Asset Management reported no remaining Tvardi Therapeutics position as of Q1 2016 after selling out during the quarter.
  • ClariVest Asset Management sold 1 Tvardi Therapeutics share in Q1 2016.
  • ClariVest Asset Management first reported a position in Tvardi Therapeutics in Q2 2014 and held it in 7 quarters.
  • ClariVest Asset Management's Tvardi Therapeutics position peaked at $546K in Q2 2014.
  • 93 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2016.

Based on ClariVest Asset Management's 13F filing for Q1 2016, filed 27 Apr 2016.